CG Oncology, Inc.
↗Irvine, USA
CG Oncology is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer. The company's innovative approach centers on oncolytic immunotherapy, utilizing engineered viruses to selectively target cancer cells while inducing a robust immune response.
The company's lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic adenovirus. It is currently being evaluated in multiple pivotal trials for Non-Muscle Invasive Bladder Cancer (NMIBC), aiming to provide an alternative to radical cystectomy for patients who have failed standard treatments like BCG therapy.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$10M
Founded:2010
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$1.1B
Investors:Decheng Capital, Longitude Capital, TCG Crossover, Foresite Capital, Wellington Management, BlackRock
STOCK
Exchange:NASDAQ
Ticker:CGON
Market Cap:$4.82B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 / BLA Submission
Modalities:Oncolytic Virus, Immunotherapy, Gene therapy
Active Trials:5
Trial Phases:Phase 2: 2 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Biovire
Key Partnerships:Kissei Pharmaceutical (Development and commercialization rights in Japan, South Korea, and Taiwan), Lepu Biopharma (Rights in Greater China)
COMPETITION
Position:Leader
Competitors:Ferring Pharmaceuticals (Adstiladrin), ImmunityBio (Anktiva), Merck (Keytruda), Johnson & Johnson
LEADERSHIP
Key Executives:
Arthur Kuan - Chairman & CEO
Ambaw Bellete - President & COO
Scientific Founders:Dr. Tai-Tsang Chen
Board Members:Arthur Kuan, Christina Rossi, Vikas Goyal, Bernardo Kirschner
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CG Oncology, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.